08:00 , Jan 23, 2012 |  BC Week In Review  |  Clinical News

Isoniazide: Phase IIa started

Bridge Bioresearch began a double-blind, placebo-controlled, U.K. Phase IIa trial to evaluate thrice-daily oral isoniazide for 12 weeks in about 60 patients with diabetic foot ulcers. Bridge Bioresearch plc , London, U.K.   Product: Isoniazide...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Company News

Bridge Bioresearch, GENova, Suncheon Cheongam College deal

GENova said it terminated a deal earlier this month with Bridge Bioresearch to share research on their respective programs. Further details were not disclosed (see BioCentury, Sept. 21). Separately, GENova signed a letter of intent...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Company News

GENova, Bridge Bioresearch, Prime BioResearch deal

GENova will acquire three patents covering undisclosed targets from an undisclosed company. GENova is developing tetanolic acid to treat breast cancer, with other compounds to treat prostate cancer. Also, in two separate deals, GENova partnered...